Department of Cardiology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
EJNMMI Res. 2014 Jan 2;4(1):1. doi: 10.1186/2191-219X-4-1.
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising modality for detecting active lesions of cardiac sarcoidosis (CS). However, determining whether 18F-FDG uptake in the myocardium is physiological is challenging due to metabolic shift in myocardial cells. Although methods for inhibiting physiological myocardial 18F-FDG uptake have been proposed, no standard methods exist. This study therefore aimed to compare the effect of an 18-h fast (long fasting (LF)) with heparin loading plus a 12-h fast (HEP) before 18F-FDG PET scan.
We analyzed the effects of LF and HEP on the inhibition of physiological myocardial 18F-FDG uptake in healthy subjects (18 in HEP and 19 in LF) and in patients with known or suspected CS (96 in HEP and 69 in LF). In CS, the lower uptake of 18F-FDG in the myocardium was evaluated. A visual four-point scale was used to assess myocardial 18F-FDG uptake in comparison with hepatic uptake (1 lower, 2 similar, 3 somewhat higher, 4 noticeably higher).
Myocardial 18F-FDG uptake was 1.68 ± 1.06 in LF and 3.17 ± 1.16 in HEP in healthy subjects (p < 0.0001), whereas it was 1.48 ± 0.99 in LF and 2.48 ± 1.33 in HEP in CS patients (p < 0.0001). Logistic regression and regression trees revealed the LF was the most effective in inhibiting myocardial 18F-FDG uptake. In addition, serum free fatty acid levels on intravenous 18F-FDG injection were a possible biomarker.
LF is effective in inhibiting myocardial 18F-FDG uptake, and consequently, it could be useful for evaluating active lesions of CS in 18F-FDG PET images.
氟-18 氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)是检测心脏结节病(CS)活性病变的一种很有前途的方法。然而,由于心肌细胞代谢转移,确定心肌 FDG 摄取是否为生理性具有挑战性。尽管已经提出了抑制心肌 18F-FDG 摄取的方法,但尚无标准方法。因此,本研究旨在比较 18 小时禁食(长禁食(LF))与肝素负荷加 12 小时禁食(HEP)对 18F-FDG PET 扫描前心肌 18F-FDG 摄取的抑制作用。
我们分析了 LF 和 HEP 对健康受试者(HEP 组 18 例,LF 组 19 例)和已知或疑似 CS 患者(HEP 组 96 例,LF 组 69 例)中抑制生理性心肌 18F-FDG 摄取的影响。在 CS 中,评估了心肌 18F-FDG 摄取的降低情况。使用视觉四点量表评估与肝摄取相比的心肌 18F-FDG 摄取(1 表示较低,2 表示相似,3 表示稍高,4 表示明显较高)。
健康受试者中,LF 组心肌 18F-FDG 摄取为 1.68±1.06,HEP 组为 3.17±1.16(p<0.0001),而 CS 患者中 LF 组为 1.48±0.99,HEP 组为 2.48±1.33(p<0.0001)。逻辑回归和回归树显示 LF 是抑制心肌 18F-FDG 摄取最有效的方法。此外,静脉注射 18F-FDG 时血清游离脂肪酸水平可能是一种生物标志物。
LF 抑制心肌 18F-FDG 摄取有效,因此它可能有助于评估 18F-FDG PET 图像中 CS 的活性病变。